22.80
0.06 (0.26%)
| Previous Close | 22.74 |
| Open | 22.52 |
| Volume | 97,558 |
| Avg. Volume (3M) | 1,463,718 |
| Market Cap | 2,827,961,088 |
| Price / Earnings (Forward) | 123.46 |
| Price / Sales | 7.53 |
| Price / Book | 14.56 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | -60.95% |
| Operating Margin (TTM) | -37.25% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 32.80% |
| Total Debt/Equity (MRQ) | 77.67% |
| Current Ratio (MRQ) | 3.55 |
| Operating Cash Flow (TTM) | -110.94 M |
| Levered Free Cash Flow (TTM) | -66.54 M |
| Return on Assets (TTM) | -18.43% |
| Return on Equity (TTM) | -70.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Arcutis Biotherapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.95% |
| % Held by Institutions | 108.79% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 31 Dec 2025 | 9,874,511 |
| Rubric Capital Management Lp | 31 Dec 2025 | 8,271,577 |
| Polar Capital Holdings Plc | 31 Dec 2025 | 5,556,169 |
| Gilder Gagnon Howe & Co Llc | 31 Dec 2025 | 4,453,856 |
| Ensign Peak Advisors, Inc | 31 Dec 2025 | 1,902,390 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 36.00 (Needham, 57.90%) | Buy |
| Median | 35.00 (53.51%) | |
| Low | 34.00 (HC Wainwright & Co., 49.12%) | Buy |
| Average | 35.00 (53.51%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 27.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 02 Mar 2026 | 35.00 (53.51%) | Buy | 24.76 |
| Guggenheim | 27 Feb 2026 | 35.00 (53.51%) | Buy | 26.97 |
| HC Wainwright & Co. | 26 Feb 2026 | 34.00 (49.12%) | Buy | 28.57 |
| Needham | 26 Feb 2026 | 36.00 (57.89%) | Buy | 28.57 |
| 26 Jan 2026 | 31.00 (35.96%) | Buy | 26.32 | |
| TD Cowen | 26 Feb 2026 | 35.00 (53.51%) | Buy | 28.57 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |